Insider activity (SEC Form 4)
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
Open-market · last 30 days:
4 buyers bought $280K
0 sellers sold $0
Open-market · last 90 days:
4 buyers bought $280K
0 sellers sold $0
| Insider | Role | Date | Transaction | Shares | Value |
|---|
| Carter Denise P. |
Chief Operating Officer, Director |
2026-08-31 |
Open-market buy |
20490 |
$100K |
| Culverwell Anthony James |
Director |
2026-08-31 |
Open-market buy |
6146 |
$30K |
| Lawlor Sally Bridget |
Chief Financial Officer |
2026-08-31 |
Open-market buy |
10244 |
$50K |
| Myers Michael |
Chief Executive Officer, Director |
2026-08-31 |
Open-market buy |
20490 |
$100K |
| Culverwell Anthony James |
Director |
2026-08-27 |
Grant/award |
31352 |
$161K |
| LANGER DENNIS |
Director |
2026-08-27 |
Grant/award |
34534 |
$178K |
| LANGER DENNIS |
Director |
2025-10-14 |
Open-market buy |
15152 |
$129K |
Most recent 7 reported transactions. Open-market buys (P) and sells (S) are the deliberate ones; grants and option exercises are compensation. Not investment advice.
8-K
filed 2026-08-28
confidence 95%
Item 1.01
Quoin entered into a Securities Purchase Agreement on August 27, 2026, for a private placement of up to $50.0 million in gross proceeds, consisting of 6,305,300 ADSs (or pre-funded warrants) and accompanying ordinary warrants to purchase 3,152,650 ADSs. The unregistered equity issuance under Section 4(a)(2) and Regulation D exemptions is structured as a PIPE-like transaction with insider participation, representing significant dilution to existing shareholders and expected to fund operations into the second half of 2029.
View raw filing on EDGAR →
8-K
filed 2026-08-28
confidence 75%
Item 8.01
Quoin announced positive interim clinical trial results from the Phase 2/3 study CL-QRX003-004 of QRX003 for Netherton Syndrome, with the primary endpoint met with statistical significance (p=0.0087 vs. α=0.0215) in 4 of 6 participants. This material clinical milestone represents a significant development in the company's late-stage specialty pharmaceutical pipeline.
View raw filing on EDGAR →
8-K
filed 2026-08-20
confidence 98%
Item 5.07
Quoin Pharmaceuticals held its Annual Meeting of shareholders on August 20, 2026, with voting results on five proposals: election of seven directors, advisory approval of named executive officer compensation, approval of non-employee director compensation changes, approval of 401(k) matching contribution changes, and appointment of the independent auditor.
View raw filing on EDGAR →
8-K
filed 2026-08-14
confidence 95%
Item 2.02
This is a standard earnings release disclosing Q2 2026 financial results for Quoin Pharmaceuticals. The filing explicitly states "On August 14, 2026 Quoin Pharmaceuticals Ltd. (the 'Company') issued a press release announcing its financial results for the quarter ended June 30, 2026," with the press release furnished as Exhibit 99.1. The exhibit contains consolidated balance sheets, statements of operations, and loss per ADS metrics for the periods ended June 30, 2026 and 2025, along with operational highlights. This is a material disclosure affecting investor assessment of the company's financial condition and operational progress.
View raw filing on EDGAR →
8-K
filed 2026-06-23
confidence 75%
Item 8.01
Quoin announced FDA conditional approval of the brand name QYLEKI™ for QRX003, its investigational treatment for Netherton Syndrome, representing a material regulatory milestone in the drug development pathway. The company expects to initiate a Phase 3 pivotal study in H2 2026 and anticipates filing an NDA in 2027, advancing the lead candidate toward potential commercialization.
View raw filing on EDGAR →
8-K
filed 2026-06-04
confidence 72%
Item 8.01
Quoin Pharmaceuticals announced that Japan's Ministry of Health, Labour and Welfare (MHLW) granted Orphan Drug Designation to QRX003 lotion for the treatment of Netherton Syndrome. This designation provides significant development incentives including prioritized consultation, reduced fees, tax benefits, priority review, and up to 10 years of market exclusivity, representing a material regulatory milestone for the company's pipeline.
View raw filing on EDGAR →